Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Journal of Immunology (Baltimore, Md. : 1950)|November 15, 1989
Structural requirements for the interaction between peptide antigens and I-Ed moleculesA Sette, L Adorini, E Appella, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|November 4, 2000
Linkage disequilibrium and haplotype mapping of a skin cancer susceptibility locus in outbred miceB Peissel, D Zaffaroni, N Zanesi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 19, 2003
Interleukin-6 release in the hepatic blood outflow during normothermic liver ischaemia in humansL Guidi, A Tricerri, M Costanzo, et al.
Minerva Ginecologica|July 20, 2004
[Prevention and treatment of congenital toxoplasmosis: organization protocol]A Vimercati, M C Angelici, L De Cosmo, et al.
Molecular Brain|August 21, 2016
Orchestrated activation of mGluR5 and CB1 promotes neuroprotectionEdleusa M L Batista, Juliana G Doria, Talita H Ferreira-Vieira, et al.
Journal of Crohn'S & Colitis|June 8, 2012
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressantsG Andrisani, D Frasca, M Romero, et al.
Neurobiology of Disease|August 28, 2014
The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's diseaseJ G Doria, J M de Souza, J N Andrade, et al.
British Journal of Pharmacology|March 16, 2013
Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's diseaseJ G Doria, F R Silva, J M de Souza, et al.
Scientific Reports|June 1, 2022
mGluR5 ablation leads to age-related synaptic plasticity impairments and does not improve Huntington's disease phenotypeJessica M de Souza, Talita H Ferreira-Vieira, Esther M A Maciel, et al.
International Journal of Immunopathology and Pharmacology|February 9, 2005
Increased levels of NF-kappaB inhibitors (IkappaBalpha and IkappaBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatmentL Guidi, M Costanzo, M Ciarniello, et al.
Pageof 18